Side-by-side · Research reference

IGF-1 LR3vsPEG-MGF

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED10/58 cited

BAnimal-MechanisticHUMAN-REVIEWED2/69 cited

IGF-1 LR3

IGF-1 Analogue · Research

3–10×Potency vs IGF-I

Low IGFBPBinding affinity

ResearchStatus

Research only · SQ typical in animal models

PEG-MGF

IGF-1Ec Splice Variant · PEGylated

~2 hrHalf-life (PEG)

~7 minNative MGF t½

IGF-1EcSplice variant

SQ · Research Protocol

01Mechanism of Action

Parameter

IGF-1 LR3

PEG-MGF

Primary target

IGF-1 receptor (IGF-1R)McTavish 2009

IGF-1 receptor on muscle satellite cells and myocytes

Pathway

IGF-1R → IRS-1 → PI3K/Akt → Cell proliferation, protein synthesis, anti-apoptosisMuhlbradt 2009

IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion

Downstream effect

Enhanced cell proliferation, muscle anabolism, inhibition of apoptosis, increased telomerase activity

Satellite cell activation, muscle fiber repair, localized hypertrophy signaling

Feedback intact?

No — exogenous IGF analogue bypasses GH-mediated regulation

Partially bypassed — does not require hepatic IGF-1 synthesis

Origin

Synthetic 83-AA analogue: 13-AA N-terminal extension + Arg substitution at position 3

IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation

Antibody development

—

Unknown — no long-term human immunogenicity data

02Dosage Protocols

Parameter

IGF-1 LR3

PEG-MGF

Research dose (animal models)

Variable by protocol and species

In vivo murine atherosclerosis studies used sustained delivery.

—

In vitro typical concentration

10–1000 ng/mLThomas 2007

Dose-dependent effects on follicle growth and estradiol production.

—

Half-maximal stimulation

0.6 nM LR3 vs 1.5 nM native IGF-1Price 2004

2.5-fold greater potency in lung fibroblast proliferation.

—

Evidence basis

Animal / in vitro only

Animal / mechanistic

Human use

Not FDA-approved; no published human trials

—

Research dose range

—

100–200 mcg

Extrapolated from animal models; no validated human protocols.

Frequency

—

Post-training or daily

Timing to match endogenous MGF pulse post-exercise.

Half-life

—

~2 hours (PEGylated)

Native MGF: ~7 min; PEGylation extends circulation.

Reconstitution

—

Sterile bacteriostatic water

Lyophilized form; store reconstituted at 2–8 °C.

PEG molecular weight

—

Typically 5–30 kDa

Higher MW = longer t½, greater steric hindrance.

Timing

—

Within 30–60 min post-training

Aligns with endogenous MGF window.

03Metabolic / Fat Loss Evidence

Parameter

IGF-1 LR3

PEG-MGF

Mechanism

IGF-1R activation → lipolytic signaling; secondary to anabolic effects

—

Direct lipolytic evidence

Minimal — primarily anabolic/anti-apoptotic in literature

—

Atherosclerotic plaque effects

Reduced stenosis and core size in ApoE-KO micevon 2011

Plaque stabilization via vSMC phenotype modulation, not direct fat loss.

—

Human data

None published

—

Primary target

—

Muscle tissue (satellite cells, myocytes) — not adipose-specific

Indirect metabolic effect

—

IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015

Mechanism distinct from direct lipolytic peptides.

Body composition

—

Lean mass preservation / hypertrophy focus

Fat loss evidence

—

No direct human or animal RCT data for PEG-MGF-driven fat reduction

04Side Effects & Safety

Parameter

IGF-1 LR3

PEG-MGF

Hypoglycemia risk

Theoretical — IGF-1 analogues can lower blood glucose

IGF-1 axis activation can lower blood glucose

Excessive cell proliferation

Mitogenic signaling; theoretical tumor promotion risk

—

Telomerase activation

2–10-fold increase in prostate cancer cells (PC-3, DU-145, LAPC-4)Wetterau 2003

Critically involved in cancer cell immortalization.

—

Oocyte degeneration

Increased oocyte degeneration at high doses (≥1000 ng/mL) in bovine folliclesThomas 2007

—

Unregulated anabolism

Bypasses physiological GH/IGF-1 feedback; no pulsatility control

—

Unknown human safety profile

No published human trials; safety data absent

—

Injection site reaction

—

Erythema, induration (common with SQ peptides)

IGF-1R overstimulation

—

Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure

Fluid retention

—

Possible with IGF-1 pathway activation (dose-dependent)

PEG accumulation

—

Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment

Antibody formation

—

PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)

Cancer risk

—

IGF-1 axis stimulation contraindicated in active malignancy

Human safety data

—

Absent — no published human trials for PEG-MGF

Absolute Contraindications

IGF-1 LR3

·Active malignancy or history of cancer
·Not approved for human use

PEG-MGF

·Active malignancy or history of cancer (IGF-1R proliferative signaling)
·Known hypersensitivity to PEGylated compounds
·Pregnancy / lactation (no reproductive toxicity data)

Relative Contraindications

IGF-1 LR3

·Diabetes or glucose intolerance
·Family history of cancer

PEG-MGF

·Diabetes (monitor glucose closely)
·Renal impairment (PEG clearance reduced)
·Retinopathy (IGF-1 axis effects on vascular proliferation)

05Administration Protocol

Parameter

IGF-1 LR3

PEG-MGF

1. Research use only

IGF-1 LR3 is not FDA-approved for human use. All administration data derives from animal or in vitro studies.

Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.

2. Typical research route

Subcutaneous or intraperitoneal injection in animal models. In vitro: added directly to culture medium at concentrations of 10–1000 ng/mL.Thomas 2007

Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.

3. Reconstitution (research)

Lyophilised powder reconstituted in sterile water or buffered saline per manufacturer protocol. Store at 2–8 °C after reconstitution.

Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.

4. Stability

Enhanced stability vs native IGF-1 due to reduced IGFBP binding; exact half-life in vivo not fully characterized in humans.

Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.

5. Needle

—

29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.

06Stack Synergy

IGF-1 LR3

+ GHRP-6

Multi-pathway

View GHRP-6 →

GHRP-6 stimulates endogenous GH release, which drives hepatic IGF-1 synthesis. IGF-1 LR3 provides exogenous, IGFBP-resistant IGF signaling. Combining upstream GH stimulation with downstream IGF receptor activation creates a dual-pathway anabolic effect. However, this bypasses natural feedback and carries compounded mitogenic risk.

GHRP-6: 100–200 mcg SQ · 2–3× daily
IGF-1 LR3: Research doses variable · post-workout typical in animal models
Note: Research context only — no human protocols exist
Primary benefit: Theoretical maximal anabolic signaling (GH + IGF axes)

+ Ipamorelin

Multi-pathway

View Ipamorelin →

Ipamorelin (selective GHRP) stimulates pulsatile GH release without cortisol/prolactin elevation. IGF-1 LR3 directly activates IGF-1R independent of GH. This stack targets both upstream (GH secretion) and downstream (IGF receptor) nodes but eliminates physiological feedback, raising safety concerns around unchecked proliferation.

Ipamorelin: 200–300 mcg SQ · evening
IGF-1 LR3: Research doses only · timing variable
Caution: No human data; animal/in vitro only
Primary benefit: Dual-axis anabolic signaling (theoretical)

PEG-MGF

+ BPC-157

Moderate

View BPC-157 →

BPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.

PEG-MGF: 100–200 mcg SQ post-training
BPC-157: 250–500 mcg SQ or oral, twice daily
Duration: 4–6 weeks (injury-dependent)
Primary benefit: Accelerated muscle and connective tissue repair, enhanced recovery

+ TB-500

Strong

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.

PEG-MGF: 100–200 mcg SQ post-training
TB-500: 2–5 mg SQ, 2× per week (loading), then weekly
Timing: Stagger injections by 6–12 hours
Primary benefit: Maximal satellite cell recruitment and myogenic differentiation, injury repair